Dr. Reddy's Laboratories is increasing focus on obesity therapies, biosimilars, peptides and consumer healthcare as lower sales from its cancer drug business in the US market weigh on growth. The company reported pressure in the North America business during Q4FY26 due to lower cancer drug sales, pricing erosion and one-time adjustments. At the same time, India, emerging markets and Europe continued to grow, supported by new launches and acquisitions. With investments in biosimilars, metabolic therapies and branded markets, Dr Reddy’s is positioning itself for its next phase of growth beyond traditional generics.